GCP
BCYC

GSA Capital Partners’s Bicycle Therapeutics BCYC Stock Holding History

GSA Capital Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$125K Buy
+26,842
New +$153K 0.01% 1541
2025
Q2 		– Sell
-11,952
Closed -$101K – 1751
2025
Q1 		$101K Buy
+11,952
New +$141K 0.01% 1496

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GSA Capital Partners's BCYC Position: Q1 2026 in Review

GSA Capital Partners opened a new position in Bicycle Therapeutics (BCYC) in Q1 2026: 26,842 shares worth $125K. The stake represents 0.01% of the portfolio and ranks #1541 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in BCYC as recently as Q1 2025.

GSA Capital Partners first reported a position in BCYC in Q1 2025 and has held it in 2 quarters since. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • GSA Capital Partners held 26,842 shares of Bicycle Therapeutics worth $125K as of Q1 2026.
  • Bicycle Therapeutics was a new GSA Capital Partners position in Q1 2026.
  • Bicycle Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1541 holding.
  • GSA Capital Partners first reported a position in Bicycle Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.